Latest news
- Business09 September 2022
CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®
Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem...
- Business02 September 2022
Our differentiated portfolio: Oral solution basket
The core strategy of Adalvo’s portfolio is innovation and differentiation, which allows us to make unique products available in the market, and supports our partners to target unmet medical needs....
- Business30 August 2022
Psoriasis Awareness Month - spotlighting Apremilast
August commemorates Psoriasis Awareness month and is used as an opportunity to educate and inform on a range of topics varying from treatment, causes, triggers and management of the inflammatory...
- Business25 August 2022
Adalvo and Hikma Sign Exclusive Licensing Agreement to Commercialise a product in the Allergic Rhinitis space across MENA Markets
Adalvo is pleased to announce that we have signed an exclusive licensing agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, to commercialise a nasal spray indicated in the treatment...
- Business23 August 2022
Adalvo advances in the pain domain, offering an extensive portfolio of pain management medication
We at Adalvo continue to strengthen our comprehensive pain management portfolio, covering a unique selection of products conducive to this indication.
- Business19 August 2022
Adalvo announces dossier submission for Pregabalin Extended Release
Adalvo is very proud to announce that our dossier for Pregabalin ER tablets has been submitted successfully. Pregabalin is a backbone medication indicated in the treatment of Neuropathic pain.
- Business12 August 2022
Adalvo announces dossier submission for Eribulin solution for injection
We are pleased to announce that our dossier submission for Eribulin solution for injection, 0.44mg/ml has been completed.
- Business09 August 2022
Adalvo Announces successful DCP closure for Fulvestrant pre-filled injection
Adalvo is pleased to announce our successful DCP closure for Fulvestrant pre-filled injection. Our product is a fully EU compliant generic version of Faslodex, which is a widely used drug,...
- Business02 August 2022
Adalvo acquires its first branded product, Onsolis®
Adalvo is thrilled to announce the acquisition of our first branded product, Onsolis® after concluding a deal with a reputable US based specialty pharmaceutical Company, who originally owned the product....
- Business28 July 2022
Adalvo Announces Successful BE Outcome for Palbociclib Film-Coated Tablets
We are pleased to announce that we have now completed our Pilot BE program for Palbociclib Film-coated Tablets, which is being developed in collaboration with our oncology specialty, sister company, forming...
- Business15 July 2022
Adalvo announces DCP approval for Dimethyl Fumarate 120mg, 240mg hard capsules
Adalvo is delighted to announce the successful DCP closure of our Dimethyl Fumarate 120mg, 240mg hard capsules in Europe.
- Business04 July 2022
Adalvo announces successful Phase III Study for Pregabalin Extended Release
Adalvo is very proud to announce that our Phase III Study for Pregabalin ER tablets has been completed successfully. The study was conducted with a patient population of over 450...
- Business23 June 2022
Adalvo is now offering over 100 products to our partners!
Adalvo is now able to offer over 100 tailor-made products to our partners. As part of our growth journey, our focus has always been to bring high-value, differentiated products, covering...
- Business21 June 2022
Adalvo Announces Successful BE Outcome for Tafamidis Meglumine 20mg Soft Gel Capsules
We are pleased to announce that we have now completed our Pivotal BE program for Tafamidis Meglumine Soft Gel Capsules 20mg.
- Business16 June 2022
Apremilast Film-Coated Tablets: DCP Status Update
Adalvo is pleased to announce that our dossier for Apremilast Film-Coated Tablets is complete and our DCP submission is scheduled for January 2023.
- Business14 June 2022
Adalvo Announces Successful Pivotal BE Program For Macitentan 10mg Film-Coated Tablets
We are pleased to announce that we have now completed our Pivotal BE program for Macitentan 10mg film-coated tablets. This product has been developed in collaboration with one of our strategic...
- Business08 June 2022
Vortioxetine Film-Coated Tablets: DCP Submission Timeline Update
Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked for the15th July 2022.
- Business02 June 2022
Cladribine: Adalvo makes good progress on a challenging development
We are pleased to announce the successful progression of Cladribine, which is being developed based on the reference brand Mavenclad (Merck) and is indicated in the treatment of Multiple Sclerosis....
- Business19 May 2022
Women Health Segment: Why is Adalvo a partner of choice?
One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. In this respect, we are now developing...
- Business11 May 2022
Adalvo announces DCP approval for Enzalutamide Soft Gel capsules
Adalvo is delighted to announce the successful EU DCP closure of our Enzalutamide Soft Gel Capsules. We believe to be the first Company to receive an EU approval, and with this...
- Business10 May 2022
A Powerful Investment Alliance of Aztiq and Innobic Acquires Alvogen Shares in Adalvo
The Consortium jointly, through Aztiq II HoldCo, has acquired a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholder in Adalvo. The Consortium’s collective industry experience,...